US regulatory status: approved. Molecular target: Dopamine receptors; D2 & D3.
- Target
- Dopamine receptors; D2 & D3
- Mechanism
- Serotonin (5-HT) receptor antagonist
biotech · Pulmonary Disease, Chronic Obstructive · Symptomatic Neurogenic Orthostatic Hypertension · TBPH
Theravance Biopharma Ireland
Theravance Biopharma Ireland Umited
Theravance Biopharma Ireland drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
901 Gateway Blvd., South San Francisco, CA 94080, US HQ
2014 Founded
177 Employees
Public company Type
TBPH · NYSE Ticker
Company details
- Status
- Public
- HQ
- 901 Gateway Blvd., South San Francisco, CA 94080, US
- Founded
- 2014
- Employees
- 177
- Programs
- 1
- Drugs
- 7
- Patents
- 11
Theravance Biopharma Ireland pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Theravance Biopharma Ireland drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
Development asset linked to Theravance Biopharma Ireland in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M3.
- Target
- Muscarinic acetylcholine receptor M3
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
telavancin
Antiinfectives for systemic use (J01)US regulatory status: approved.
-
umeclidinium
Respiratory system (R03)Respiratory system (R03) compound in Theravance Biopharma Ireland's portfolio. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist